You just read:

First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma

News provided by

Innovent Biologics, Inc.

Feb 27, 2019, 19:30 ET